Lexaria Bioscience Corp. (LEXX)
1.23
+0.07
(+6.03%)
USD |
NASDAQ |
Dec 11, 16:00
1.24
+0.01
(+0.81%)
After-Hours: 20:00
Lexaria Bioscience Cash from Investing (Quarterly): -0.1579M for Aug. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Oncolytics Biotech, Inc. | -0.0051M |
| Aurinia Pharmaceuticals, Inc. | -14.04M |
| Edesa Biotech, Inc. | 0.00 |
| Xenon Pharmaceuticals, Inc. | 38.76M |
| ProMIS Neurosciences, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -2.642M |
| Free Cash Flow | -10.55M |
| Free Cash Flow Per Share (Quarterly) | -0.1358 |
| Free Cash Flow to Equity (Quarterly) | -2.650M |
| Free Cash Flow to Firm (Quarterly) | -2.657M |
| Free Cash Flow Yield | -47.63% |